ViiV Submits NDA for Once-Per-Month HIV Injectable

HIV-focused ViiV Healthcare submitted a New Drug Application to the U.S. Food and Drug Administration (FDA) for potential approval of its investigational combination treatment for HIV-1. Submission of the NDA comes less than a month after ViiV snagged regulatory approval of Dovato.